Skip to Main Content

Advertisement

Skip Nav Destination

HJM-561, a potent, selective and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations

Mol Cancer Ther molcanther.0835.2021.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal